Literature DB >> 27872475

Systemic lupus erythematosus: Extent and patterns of off-label use of rituximab for SLE.

Iñaki Sanz1.   

Abstract

Entities:  

Year:  2016        PMID： 27872475      PMCID： PMC5476200          DOI： 10.1038/nrrheum.2016.191

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  The landscape after LUNAR: rituximab's crater-filled path.

Authors:  Liz Lightstone
Journal:  Arthritis Rheum       Date:  2012-01-09

Review 2.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

3.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

Review 4.  A critical review of clinical trials in systemic lupus erythematosus.

Authors:  M A Mahieu; V Strand; L S Simon; P E Lipsky; R Ramsey-Goldman
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

Review 5.  Lupus nephritis management guidelines compared.

Authors:  Suzanne Wilhelmus; Ingeborg M Bajema; George K Bertsias; Dimitrios T Boumpas; Caroline Gordon; Liz Lightstone; Vladimir Tesar; David R Jayne
Journal:  Nephrol Dial Transplant       Date:  2015-04-28       Impact factor: 5.992

6.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.

Authors:  Marie B Condon; Damien Ashby; Ruth J Pepper; H Terence Cook; Jeremy B Levy; Megan Griffith; Tom D Cairns; Liz Lightstone
Journal:  Ann Rheum Dis       Date:  2013-06-05       Impact factor: 19.103

7.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

8.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

9.  A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.

Authors:  Tim Y-T Lu; Kristine P Ng; Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael Ehrenstein; David A Isenberg
Journal:  Arthritis Rheum       Date:  2009-04-15

10.  Off-label use of rituximab for systemic lupus erythematosus in Europe.

Authors:  Monica Rydén-Aulin; Dimitrios Boumpas; Irene Bultink; Jose Luis Callejas Rubio; Luis Caminal-Montero; Antoni Castro; Agustín Colodro Ruiz; Andrea Doria; Thomas Dörner; Cristina Gonzalez-Echavarri; Elisa Gremese; Frederic A Houssiau; Tom Huizinga; Murat Inanç; David Isenberg; Annamaria Iuliano; Søren Jacobsen; Juan Jimenéz-Alonso; Lászlo Kovács; Xavier Mariette; Marta Mosca; Ola Nived; Joaquim Oristrell; Manuel Ramos-Casals; Javier Rascón; Guillermo Ruiz-Irastorza; Luis Sáez-Comet; Gonzalo Salvador Cervelló; Gian Domenico Sebastiani; Danilo Squatrito; Gabriella Szücs; Alexandre Voskuyl; Ronald van Vollenhoven
Journal:  Lupus Sci Med       Date:  2016-09-06
  10 in total
  3 in total

Review 1.  [Collagenosis and vasculitis-what is allowed in treatment?]

Authors:  F Moosig; J Holle
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

2.  Autoimmune Thrombotic Thrombocytopenic Purpura: Two Rare Cases Associated with Juvenile Idiopathic Arthritis and Multiple Sclerosis.

Authors:  Despoina Dimopoulou; Athina Dimosiari; Eudokia Mandala; Theodoros Dimitroulas; Alaxandros Garyfallos
Journal:  Front Med (Lausanne)       Date:  2017-07-24

3.  Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated.

Authors:  Chunmei Wu; Qiong Fu; Qiang Guo; Sheng Chen; Shyamal Goswami; Shuhui Sun; Teng Li; Xingjian Cao; Fuying Chu; Zechuan Chen; Mei Liu; Yuanhua Liu; Ting Fu; Pei Hao; Yi Hao; Nan Shen; Chunde Bao; Xiaoming Zhang
Journal:  Ann Rheum Dis       Date:  2019-05-29       Impact factor: 19.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.